Crossref
WU-KONG28: Sunvozertinib as a Potential Chemotherapy-Sparing First-Line Option for EGFR Exon 20 Insertion-Mutant Advanced NSCLC
Malignancy Spectrum · 2026 · 1
DOI: 10.15302/msp.2026.0020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Malignancy Spectrum, 2026. Verfasst von Runliang Ni und 1 weiteren Autor:innen. Die Arbeit nennt 7 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Ni, R., & Ding, Y. (2026). WU-KONG28: Sunvozertinib as a Potential Chemotherapy-Sparing First-Line Option for EGFR Exon 20 Insertion-Mutant Advanced NSCLC. Malignancy Spectrum, 1. https://doi.org/10.15302/msp.2026.0020
Vancouver
Ni R, Ding Y. WU-KONG28: Sunvozertinib as a Potential Chemotherapy-Sparing First-Line Option for EGFR Exon 20 Insertion-Mutant Advanced NSCLC. Malignancy Spectrum. 2026:1. doi:10.15302/msp.2026.0020
BibTeX
@article{Ni2026,
author = {Ni, Runliang and Ding, Yuwei},
title = {WU-KONG28: Sunvozertinib as a Potential Chemotherapy-Sparing First-Line Option for EGFR Exon 20 Insertion-Mutant Advanced NSCLC},
journal = {Malignancy Spectrum},
year = {2026},
pages = {1},
doi = {10.15302/msp.2026.0020}
}
EUVIMED